Pfizer Inc. $PFE Shares Sold by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 16.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 444,354 shares of the biopharmaceutical company’s stock after selling 89,208 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Pfizer were worth $11,064,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PFE. Horizon Financial Services LLC raised its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. YANKCOM Partnership purchased a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the third quarter valued at approximately $29,000. Darwin Wealth Management LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $32,000. Finally, Torren Management LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.8%

PFE stock opened at $25.74 on Friday. Pfizer Inc. has a 52 week low of $22.09 and a 52 week high of $28.75. The company has a market cap of $146.70 billion, a price-to-earnings ratio of 19.65 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business has a fifty day simple moving average of $27.01 and a 200-day simple moving average of $26.19.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won European Commission approval to expand HYMPAVZI (marstacimab) for hemophilia A or B patients with inhibitors, a new label expansion that could support future revenue growth. Pfizer wins Hympavzi label expansion Europe
• Positive Sentiment: Pfizer also highlighted ongoing pipeline progress, including a new Japan RSV vaccine phase 3 trial and a prazosin site-transfer study, signaling continued development activity and supply-chain execution. Pfizer’s New Japan RSV Vaccine Trial Pfizer’s Prazosin Site-Transfer Trial
• Positive Sentiment: Some commentary argues Pfizer has effectively “locked in” several years of growth by clearing a major patent hurdle and redirecting cash toward other profit centers, which supports the bull case. Pfizer Just Locked In Its Next 5 Years of Growth

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PFE. HSBC boosted their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.84.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.